Literature DB >> 30985480

Targeted Biopsy Validation of Peripheral Zone Prostate Cancer Characterization With Magnetic Resonance Fingerprinting and Diffusion Mapping.

Ananya Panda, Gregory OʼConnor1, Wei Ching Lo2, Yun Jiang3, Seunghee Margevicius4, Mark Schluchter4, Lee E Ponsky5, Vikas Gulani1,2,6.   

Abstract

OBJECTIVE: This study aims for targeted biopsy validation of magnetic resonance fingerprinting (MRF) and diffusion mapping for characterizing peripheral zone (PZ) prostate cancer and noncancers.
MATERIALS AND METHODS: One hundred four PZ lesions in 85 patients who underwent magnetic resonance imaging were retrospectively analyzed with apparent diffusion coefficient (ADC) mapping, MRF, and targeted biopsy (cognitive or in-gantry). A radiologist blinded to pathology drew regions of interest on targeted lesions and visually normal peripheral zone on MRF and ADC maps. Mean T1, T2, and ADC were analyzed using linear mixed models. Generalized estimating equations logistic regression analyses were used to evaluate T1 and T2 relaxometry combined with ADC in differentiating pathologic groups.
RESULTS: Targeted biopsy revealed 63 cancers (low-grade cancer/Gleason score 6 = 10, clinically significant cancer/Gleason score ≥7 = 53), 15 prostatitis, and 26 negative biopsies. Prostate cancer T1, T2, and ADC (mean ± SD, 1660 ± 270 milliseconds, 56 ± 20 milliseconds, 0.70 × 10 ± 0.24 × 10 mm/s) were significantly lower than prostatitis (mean ± SD, 1730 ± 350 milliseconds, 77 ± 36 milliseconds, 1.00 × 10 ± 0.30 × 10 mm/s) and negative biopsies (mean ± SD, 1810 ± 250 milliseconds, 71 ± 37 milliseconds, 1.00 × 10 ± 0.33 × 10 mm/s). For cancer versus prostatitis, ADC was sensitive and T2 specific with comparable area under curve (AUC; (AUCT2 = 0.71, AUCADC = 0.79, difference between AUCs not significant P = 0.37). T1 + ADC (AUCT1 + ADC = 0.83) provided the best separation between cancer and negative biopsies. Low-grade cancer T2 and ADC (mean ± SD, 75 ± 29 milliseconds, 0.96 × 10 ± 0.34 × 10 mm/s) were significantly higher than clinically significant cancers (mean ± SD, 52 ± 16 milliseconds, 0.65 ± 0.18 × 10 mm/s), and T2 + ADC (AUCT2 + ADC = 0.91) provided the best separation.
CONCLUSIONS: T1 and T2 relaxometry combined with ADC mapping may be useful for quantitative characterization of prostate cancer grades and differentiating cancer from noncancers for PZ lesions seen on T2-weighted images.

Entities:  

Mesh:

Year:  2019        PMID: 30985480      PMCID: PMC6602844          DOI: 10.1097/RLI.0000000000000569

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  46 in total

1.  Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score.

Authors:  Olivio F Donati; Asim Afaq; Hebert Alberto Vargas; Yousef Mazaheri; Junting Zheng; Chaya S Moskowitz; Hedvig Hricak; Oguz Akin
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

2.  Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer.

Authors:  Alice C Yu; Chaitra Badve; Lee E Ponsky; Shivani Pahwa; Sara Dastmalchian; Matthew Rogers; Yun Jiang; Seunghee Margevicius; Mark Schluchter; William Tabayoyong; Robert Abouassaly; Debra McGivney; Mark A Griswold; Vikas Gulani
Journal:  Radiology       Date:  2017-02-10       Impact factor: 11.105

3.  Repeatability of magnetic resonance fingerprinting T1 and T2 estimates assessed using the ISMRM/NIST MRI system phantom.

Authors:  Yun Jiang; Dan Ma; Kathryn E Keenan; Karl F Stupic; Vikas Gulani; Mark A Griswold
Journal:  Magn Reson Med       Date:  2016-10-27       Impact factor: 4.668

4.  Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?

Authors:  Baris Turkbey; Vijay P Shah; Yuxi Pang; Marcelino Bernardo; Sheng Xu; Jochen Kruecker; Julia Locklin; Angelo A Baccala; Ardeshir R Rastinehad; Maria J Merino; Joanna H Shih; Bradford J Wood; Peter A Pinto; Peter L Choyke
Journal:  Radiology       Date:  2010-12-21       Impact factor: 11.105

5.  Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology.

Authors:  Daniel I Glazer; Elmira Hassanzadeh; Andriy Fedorov; Olutayo I Olubiyi; Shayna S Goldberger; Tobias Penzkofer; Trevor A Flood; Paul Masry; Robert V Mulkern; Michelle S Hirsch; Clare M Tempany; Fiona M Fennessy
Journal:  Abdom Radiol (NY)       Date:  2017-03

6.  Quantitative Analysis of Prostate Multiparametric MR Images for Detection of Aggressive Prostate Cancer in the Peripheral Zone: A Multiple Imager Study.

Authors:  Au Hoang Dinh; Christelle Melodelima; Rémi Souchon; Jérôme Lehaire; Flavie Bratan; Florence Mège-Lechevallier; Alain Ruffion; Sébastien Crouzet; Marc Colombel; Olivier Rouvière
Journal:  Radiology       Date:  2016-02-09       Impact factor: 11.105

7.  Diagnosis of Prostate Cancer with Noninvasive Estimation of Prostate Tissue Composition by Using Hybrid Multidimensional MR Imaging: A Feasibility Study.

Authors:  Aritrick Chatterjee; Roger M Bourne; Shiyang Wang; Ajit Devaraj; Alexander J Gallan; Tatjana Antic; Gregory S Karczmar; Aytekin Oto
Journal:  Radiology       Date:  2018-02-02       Impact factor: 11.105

8.  Feasibility and preliminary experience of quantitative T2* mapping at 3.0 T for detection and assessment of aggressiveness of prostate cancer.

Authors:  Lian-Ming Wu; Xiao-Xi Chen; Han-Qing Xuan; Qiang Liu; Si-Teng Suo; Jiani Hu; Jian-Rong Xu
Journal:  Acad Radiol       Date:  2014-08       Impact factor: 3.173

9.  Performance of a fast and high-resolution multi-echo spin-echo sequence for prostate T2 mapping across multiple systems.

Authors:  Petra J van Houdt; Harsh K Agarwal; Laurens D van Buuren; Stijn W T P J Heijmink; Søren Haack; Henk G van der Poel; Ghazaleh Ghobadi; Floris J Pos; Johannes M Peeters; Peter L Choyke; Uulke A van der Heide
Journal:  Magn Reson Med       Date:  2017-07-03       Impact factor: 4.668

10.  Magnetic Resonance Fingerprinting-An Overview.

Authors:  Ananya Panda; Bhairav B Mehta; Simone Coppo; Yun Jiang; Dan Ma; Nicole Seiberlich; Mark A Griswold; Vikas Gulani
Journal:  Curr Opin Biomed Eng       Date:  2017-09
View more
  13 in total

1.  Magnetic resonance fingerprinting in prostate cancer before and after contrast enhancement.

Authors:  Young Sub Lee; Moon Hyung Choi; Young Joon Lee; Dongyeob Han; Dong-Hyun Kim
Journal:  Br J Radiol       Date:  2021-08-20       Impact factor: 3.039

2.  Toward magnetic resonance fingerprinting for low-field MR-guided radiation therapy.

Authors:  Nikolai J Mickevicius; Joshua P Kim; Jiwei Zhao; Zachary S Morris; Newton J Hurst; Carri K Glide-Hurst
Journal:  Med Phys       Date:  2021-09-18       Impact factor: 4.071

Review 3.  MR fingerprinting of the prostate.

Authors:  Wei-Ching Lo; Ananya Panda; Yun Jiang; James Ahad; Vikas Gulani; Nicole Seiberlich
Journal:  MAGMA       Date:  2022-04-13       Impact factor: 2.533

Review 4.  New prostate MRI techniques and sequences.

Authors:  Aritrick Chatterjee; Carla Harmath; Aytekin Oto
Journal:  Abdom Radiol (NY)       Date:  2020-12

5.  Rapid high-resolution volumetric T1 mapping using a highly accelerated stack-of-stars Look Locker technique.

Authors:  Zhitao Li; Zhiyang Fu; Mahesh Keerthivasan; Ali Bilgin; Kevin Johnson; Jean-Philippe Galons; Srinivasan Vedantham; Diego R Martin; Maria I Altbach
Journal:  Magn Reson Imaging       Date:  2021-03-17       Impact factor: 3.130

6.  The effect of gadolinium-based contrast agent administration on magnetic resonance fingerprinting-based T1 relaxometry in patients with prostate cancer.

Authors:  Nikita Sushentsev; Joshua D Kaggie; Guido Buonincontri; Rolf F Schulte; Martin J Graves; Vincent J Gnanapragasam; Tristan Barrett
Journal:  Sci Rep       Date:  2020-11-24       Impact factor: 4.379

7.  Reproducibility of magnetic resonance fingerprinting-based T1 mapping of the healthy prostate at 1.5 and 3.0 T: A proof-of-concept study.

Authors:  Nikita Sushentsev; Joshua D Kaggie; Rhys A Slough; Bruno Carmo; Tristan Barrett
Journal:  PLoS One       Date:  2021-01-29       Impact factor: 3.240

8.  Three-dimensional nuclear magnetic resonance spectroscopy: a complementary tool to multiparametric magnetic resonance imaging in the identification of aggressive prostate cancer at 3.0T.

Authors:  Michael Deal; Florian Bardet; Paul-Michael Walker; Mathilde Funes de la Vega; Alexandre Cochet; Luc Cormier; Imad Bentellis; Romaric Loffroy
Journal:  Quant Imaging Med Surg       Date:  2021-08

9.  T1 and T2 MR fingerprinting measurements of prostate cancer and prostatitis correlate with deep learning-derived estimates of epithelium, lumen, and stromal composition on corresponding whole mount histopathology.

Authors:  Rakesh Shiradkar; Ananya Panda; Patrick Leo; Andrew Janowczyk; Xavier Farre; Nafiseh Janaki; Lin Li; Shivani Pahwa; Amr Mahran; Christina Buzzy; Pingfu Fu; Robin Elliott; Gregory MacLennan; Lee Ponsky; Vikas Gulani; Anant Madabhushi
Journal:  Eur Radiol       Date:  2020-09-02       Impact factor: 5.315

Review 10.  Variability and Standardization of Quantitative Imaging: Monoparametric to Multiparametric Quantification, Radiomics, and Artificial Intelligence.

Authors:  Akifumi Hagiwara; Shohei Fujita; Yoshiharu Ohno; Shigeki Aoki
Journal:  Invest Radiol       Date:  2020-09       Impact factor: 10.065

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.